Novalgine (Metamizole Sodium Monohydrate)

• Novalgine (metamizole sodium) is employed for the management of pain and fever by inhibiting prostaglandin synthesis.
• Pain: Provides effective analgesia for acute moderate to severe pain, including musculoskeletal injuries, postoperative discomfort, and visceral pain, improving patient mobility.
• Fever: Reduces elevated body temperature in febrile conditions, offering rapid antipyretic action that helps prevent complications of high fever.
• Postoperative pain: Controls pain following surgical procedures, facilitating patient comfort, early mobilization, and smoother postoperative recovery.
• Colic: Alleviates severe abdominal cramping and discomfort associated with intestinal colic, contributing to faster symptom relief.

• Metamizole sodium acts as a non‑opioid analgesic by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins involved in pain and fever pathways. The drug also exerts central effects on the spinal cord and brainstem, contributing to its antipyretic and analgesic properties without significant interaction with opioid receptors. It does not significantly affect platelet aggregation, and its analgesic effect is comparable to that of other non‑steroidal anti‑inflammatory drugs, though the exact molecular binding profile remains partially characterized.

Novalgine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypotension: transient drop in blood pressure after injection.
• Nausea: mild to moderate nausea.
• Dizziness: feeling of light‑headedness.
• Injection site pain: local discomfort or erythema.
• Rash: mild skin irritation.
• Headache: mild headache.
• Fever: transient low‑grade fever.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening.
• Anaphylaxis: acute allergic reaction with respiratory distress.
• Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.
• Severe hypotension: prolonged low blood pressure requiring intervention.
• Blood dyscrasias: abnormal blood cell counts.

• When using Novalgine, clinicians should observe specific precautions to minimize risks.
• Assess renal function: adjust use in patients with severe renal impairment.
• Monitor blood counts: regular CBC testing to detect agranulocytosis early.
• Avoid in known hypersensitivity: do not administer to patients allergic to pyrazolones.
• Caution with anticoagulants: increased bleeding risk may occur.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Novalgine can interact with several medicines; awareness of major and moderate interactions helps ensure safe therapy.

Major Interactions (Avoid)

• Concurrent myelotoxic drugs: increased risk of agranulocytosis.
• ACE inhibitors: may potentiate hypotensive effects.
• Other NSAIDs: additive renal toxicity and gastrointestinal risk.

Moderate Interactions (Monitor Closely)

• Anticoagulants: heightened bleeding tendency.
• Diuretics: may enhance hypotensive response.
• Lithium: possible increase in serum lithium levels.